ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GILD Stock Price » GILD Stock News

Gilead Sciences Share News

 Gilead Sciences (mm) Stock Price
GILD Stock Price
 Gilead Sciences (mm) Stock Chart
GILD Stock Chart
 Gilead Sciences (mm) Stock News
GILD Stock News
 Gilead Sciences (mm) Company Information
GILD Company Information
 Gilead Sciences (mm) Stock Trades
GILD Stock Trades

FDA Approves Truvada to Prevent HIV Infection

WASHINGTON--The U.S. Food and Drug Administration Monday approved a Gilead Sciences Inc. (GILD) HIV drug for use in certain healthy people to help prevent them from contracting the virus that causes AIDS. Truvada was previously approved for use in combination with other drugs to treat HIV. The new approval will allow the drug to be used in people who are considered at high risk of becoming infected with HIV, such as those people have an HIV-infected partner. The FDA said Truvada, a pill taken daily, is to be used in combination with safe-sex practices, such as condom use, to cut the risk of sexually acquired HIV infection in adults. The agency said doctors need to test patients to make sure they are HIV-negative before prescribing Truvada as a prevention tool as well as do follow-up testing every three months. The use of Truvada alone in a person who might become infected with HIV won't treat the virus effectively. "Today's approval marks an important milestone in our fight against HIV," said FDA Commissioner Margaret A. Hamburg in a statement. "Every year, about 50,000 U.S. adults and adolescents are diagnosed with HIV infection, despite the availability of prevention methods and strategies to educate, test, and care for people living with the disease," Dr. Hamburg said.

Stock News for Gilead Sciences (GILD)
DateTimeHeadline
05/24/201511:01:02Warren Buffett's Portfolio: 3 Biotech Stocks the Oracle of Omaha...
05/23/201514:03:02Healthcare Investment Opportunities for the Long Term
05/21/201515:54:02Johnson & Johnson Just Stepped Up Its Hepatitis C Game
05/21/201508:59:02MannKind, Front and Center: The Best Product Doesnât Always E...
05/21/201508:05:02Following Hepatitis C, This Could Be the Next Disease Researchers...
05/20/201516:14:31Johnson & Johnson Takes On Gilead Sciences in Hep C... Again
05/20/201512:15:10What Is the S&P 500 Index?
05/20/201511:40:40Why Achillion Pharmaceuticals, Inc. Shares Are Collapsing
05/20/201510:06:02SWOT Analysis of Gilead Sciences Inc. Stock
05/20/201509:00:00Patent Challenges In Five Countries Dispute Validity Of Gilead's...
05/20/201509:00:00Patent Challenges In Five Countries Dispute Validity Of Gilead's...
05/20/201508:04:02How Celgene Stock Is Breaking All the Rules
05/19/201519:26:50Statement of Changes in Beneficial Ownership (4)
05/19/201519:26:20Statement of Changes in Beneficial Ownership (4)
05/19/201519:25:51Statement of Changes in Beneficial Ownership (4)
05/18/201519:11:02The Best Blue Chips to Own Forever
05/18/201517:00:00Gilead Sciences to Present at the UBS 2015 Global Healthcare...
05/18/201515:53:15Why Achillion Pharmaceuticals, Inc. Shares Soared Today
05/18/201508:51:31This Experimental Drug Could Finally Cure HIV
05/18/201508:05:023 Types of Risks Facing Biotech Stocks

Gilead Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad